Showing results (111-120 of 152) with videos related to
Sort By:
Pageof 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2013
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTOGeraldine Gebhart, Cristina Gámez, Eileen Holmes, et al.Plos One|August 8, 2019
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE studySerena Di Cosimo, Nicla La Verde, Anna Moretti, et al.Science Translational Medicine|March 11, 2026
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic valueCarolina Reduzzi, Eleonora Nicolò, Lorenzo Gerratana, et al.European Journal of Cancer (Oxford, England : 1990)|May 14, 2025
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trialChiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory AnalysisSara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.Cancer Medicine|December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studySara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.Pageof 16